---
schema_version: "secwatch.filing_event.v1"
accession: "0001178913-26-003761"
form_type: "8-K"
ticker: "SLXN"
cik: "0002022416"
company_name: "Silexion Therapeutics Corp"
filed_at: "2026-08-03T13:28:21+00:00"
generated_at: "2026-08-03T13:29:05.497878+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.25
calibrated_materiality_score: 0.25
confidence: "high"
source: SEC EDGAR
---

# Silexion Therapeutics appoints Avner Lushi to audit committee after Peled resignation

## Summary
- Professor Amnon Peled resigned from board and audit committee effective Aug 1, 2026 for personal reasons, no disagreement.
- Avner Lushi, existing independent board member, appointed to audit committee effective Aug 1, 2026.
- Audit committee now has three independent members: Dror J. Abramov (Chair), Ruth Alon, and Avner Lushi, restoring Nasdaq compliance.
- Lushi is Managing Partner and CEO of Guangzhou Sino-Israel Bio-industry Investment Fund (GIBF).

## SEC filing metadata
- accession: 0001178913-26-003761
- form_type: 8-K
- ticker: SLXN
- cik: 0002022416
- company_name: Silexion Therapeutics Corp
- filed_at: 2026-08-03T13:28:21+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.25
- calibrated_materiality_score: 0.25
- confidence: high
- sec_items: 8.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/2022416/000117891326003761/0001178913-26-003761-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/2022416/000117891326003761/zk2635816.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001178913-26-003761
- JSON: https://secwatch.observer/filing/0001178913-26-003761.json
- Plain text: https://secwatch.observer/filing/0001178913-26-003761.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.